—

BeiGene, Ltd.(ONC)— 同类公司组

数据截至2026-11-02 — 评分每个交易日晚间重新计算。分组标准=首先为共同的Closelook指数成分,其次为行业。Closelook研究日记,不构成投资建议。

BeiGene, Ltd.的Closelook综合评分为64/100,在同类公司组内排名第2位(共7家)——组内评分最高的是Halozyme Therapeutics Inc(73/100)。

名称综合动量质量估值信号距52周高点
ONC BeiGene, Ltd.64836430info7%
HALO Halozyme Therapeutics Inc73979438ok3.8%
ARGX.BR Argen-X64747529info15.2%
UCB.BR UCB SA64727144info3.5%
ARGX argenx NV ADR63687429info18.4%
REGN Regeneron Pharmaceuticals Inc62887148bull0.8%
RIGL Rigel Pharmaceuticals Inc62969072ok3.9%

评分为Closelook全部覆盖范围内的相对读数——方法论见公司评分说明。信号灯来自每日夜间信号看板。

FAQ · from the current data · as of 2026-11-02

Quick answers

BeiGene, Ltd.在Closelook覆盖范围内的同类公司有哪些?

分组首先基于共同的Closelook指数成分,其次基于行业:Halozyme Therapeutics Inc (HALO)、Argen-X (ARGX.BR)、UCB SA (UCB.BR)、argenx NV ADR (ARGX)、Regeneron Pharmaceuticals Inc (REGN)、Rigel Pharmaceuticals Inc (RIGL)。

ONC相对同类公司的评分如何?

BeiGene, Ltd.的综合评分为64/100,组内排名第2位(共7家),截至2026-11-02;组内最高综合评分为Halozyme Therapeutics Inc(73/100)。Closelook评分为研究日记读数,不构成评级或投资建议。

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.